Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2024

Which patients should we treat beyond progression and when should we stop?

What are the types of progression?

Date

16 Sep 2024

Session

Which patients should we treat beyond progression and when should we stop?

Topics

Immunotherapy

Tumour Site

Presenters

Stephane Champiat

Authors

S. Champiat

Author affiliations

  • Department Of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 77030 - Houston/US

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Presentation of case/condition

Presenter: Fiona Thistlethwaite

Session: Which patients should we treat beyond progression and when should we stop?

Resources:

Slides

Webcast

How do we manage patient progression?

Presenter: Fiona Thistlethwaite

Session: Which patients should we treat beyond progression and when should we stop?

Resources:

Slides

Webcast

Discussion

Session: Which patients should we treat beyond progression and when should we stop?

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.